Global Intravenous Immunoglobulin Market Size & Outlook

Immunodeficiency diseases was the largest segment with a revenue share of 20.04% in 2023. Horizon Databook has segmented the Global intravenous immunoglobulin market based on immunodeficiency diseases, cidp, hypogammaglobulinemia, congenital aids, chronic lymphocytic leukemia, myasthenia gravis, multifocal motor neuropathy, itp, kawasaki disease, guillain-barre syndrome covering the revenue growth of each sub-segment from 2018 to 2030.

Market Dynamics

Primary Immune Deficiency (PID) diseases represent a group of disorders characterized by a complete lapse in the immune system. There are over 430 different PIDs such as specific antibody deficiency, X-ined hypogammaglobulinemia, Wiscott -Aldrich syndrome, Di George syndrome, and Ataxia-telangectasia, among others. 

The most common uses of intravenous immunoglobulin are seen the treatment of Gullian Barre syndrome, multifocal motor neuropathy, chronic inflammatory demyelinating polyneuropathy, dermatomyositis and inflammatory myopathies, Myasthenia gravis, Lambert & Eaton syndrome, and stiff person syndrome, among others. As per a study published by U.S. 

National Library of Medicine and National Institute of Health, approximately 6 million patients are typically affected by PID worldwide with almost 90% of these cases remaining undiagnosed. Individuals suffering from PIDs are therefore vulnerable to other infections and other severe autoimmunity, malignancy, auto inflammation, and allergies.